Navigation Links
Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab)
Date:12/3/2008

he future of ACTEMRA and is committed to making this important new therapy available to patients with RA."

Roche submitted the BLA for ACTEMRA to the FDA on November 18, 2007. The BLA for ACTEMRA is based on the results of an extensive multi-national clinical development program, which included more than 4,000 patients in 41 countries, including the U.S. These studies demonstrated that treatment with ACTEMRA - alone or combination with methotrexate or other DMARDs (disease modifying anti-rheumatic drugs) - significantly reduced RA signs and symptoms, regardless of previous therapy or disease severity, compared with DMARDs alone. On July 29, 2008, the Arthritis Advisory Committee of the FDA voted 10-1 to recommend approval of ACTEMRA.

On December 3, 2008, the Swiss authorities approved RoActemra (tocilizumab, known as ACTEMRA outside the EU) for the treatment of moderately severe to severe, active rheumatoid arthritis in adult patients who did not respond adequately to treatment with DMARDs or tumor necrosis factor (TNF) inhibitors. RoActemra can be administered as a monotherapy or in combination with methotrexate and/or other conventional DMARDs. There are no significant post-approval commitments required.

On November 21, 2008, Roche announced that the European Committee on Human Medicinal Products (CHMP) provided a positive recommendation for RoActemra. This recommendation is for use of RoActemra in combination with methotrexate for the treatment of adult patients with moderate to severe RA who have either responded inadequately to, or who were intolerant to, previous therapy with one or more DMARDs or TNF antagonists. In these patients, RoActemra can be given as monotherapy in cases of intolerance to methotrexate or where continued treatment with methotrexate is inappropriate.

About ACTEMRA(R) (tocilizumab)

ACTEMRA i
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
2. Memory Pharmaceuticals and Roche Expand R3487/MEM 3454 Development Program
3. National Jewish Health and Roche Diagnostics Corporation Reach Agreement to Pursue Environmental Molecular Diagnostics Opportunities
4. MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis
5. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
6. Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials
7. New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
8. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
9. Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing
10. MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection
11. Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... VIEW, California , 20 de octubre de ... líder en el campo de la pulmonología intervencional, ... su Estudio RENEW, casi 3 meses antes de ... fundamental de exención de dispositivo de investigación (IDE) ... Medicamentos) para el sistema de espiral de reducción ...
(Date:10/20/2014)... Oct. 20, 2014 Valeritas, Inc., a leader ... patients with Type 2 diabetes, announced today that it ... Award. The award was presented October 16 th ... Columbus, Ohio . The Cardinal ... a variety of metrics specifically targeted at the importance ...
(Date:10/20/2014)... Oct. 20, 2014 Lpath, Inc. (NASDAQ: ... bioactive lipid-targeted therapeutics, received official notification from the European ... another key patent supporting its iSONEP™ and ASONEP™ ... European patent No. 2087002, claims compositions of matter ... two lead compounds, iSONEP and ASONEP. Sonepcizumab is ...
Breaking Medicine Technology:PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4
... Company (Nasdaq: PRGO;TASE) today announced that Perrigo CFO Judy Brown ... 5, 2011 at 9:30 a.m. (IST) at the TASE Headquarters ... The day will include presentations on the Consumer Healthcare, ... and research and development. Perrigo Company is ...
... PARK, Calif., Oct. 4, 2011 CV Ingenuity, a ... a $16 million Series B round of financing led ... capital firm. Existing investors BioStar Ventures, Synergy Ventures and ... (CVI), which is focused on the development of a ...
Cached Medicine Technology:CV Ingenuity Announces Close of $16 Million Series B Financing Led by NEA 2
(Date:10/20/2014)... Silver Spring, Maryland, USA (PRWEB) October 20, 2014 ... readers or to track interventions? Here comes a wonderful ... leading mobile app development company helped its ... track Intervention more efficiently. The app is designed for ... iPad, and iPod touch. This app is optimized for ...
(Date:10/19/2014)... Recently, BambooIndustry.com, one of the most popular suppliers of ... bamboo deckings . Moreover, the company has launched a ... available at deeply discounted rates. , As is ... the significance of online business nowadays. Thus, BambooIndustry.com pays ... workers are striving to deliver both value and efficiency ...
(Date:10/19/2014)... Having been working in the garment industry for decades, ... According to James, one of the company’s top designers, many ... high-low skirts that add beauty to them. Chiffon floor length ... unveiled its new selection of 2014 long prom dresses. ... items are available in over 20 popular designs. The company ...
(Date:10/19/2014)... 2014 SweetDressy.com, a professional company of ... promotion for long evening dresses . All the ... offer; the current discount is up to 66 percent ... pioneers in the fashion field. Its dress specialists are ... in various parts of the world. All the company’s ...
(Date:10/19/2014)... Oct. 19, 2014 (HealthDay News) -- New stem cell-based ... lead to new treatments, a new study suggests. ... human intestinal tissue in a lab dish. They then ... for studying intestinal disorders, according to the researchers. ... diseases and conditions that can cause intestinal failure, from ...
Breaking Medicine News(10 mins):Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2Health News:Scientists Grow, Implant Human Intestinal Tissue in Mice 2
... that the actress' current rehab spell will bring a stop ... incidents . ,As the Mean Girls star checked ... 28, after being arrested for DUI, her supposed friends got ... ,One friend told America's Star magazine that Lohan attempted to ...
... Laboratories Inc. today announced that Mylan Pharmaceuticals Inc. ... and Drug Administration (FDA) for its Abbreviated ... Tablets, 12.5 mg and 25 mg. ,Mylan's ... June 29, 2007, concurrent with the expiration of ...
... the explosive growth of smoke-free air laws worldwide ... now protected by laws that require smoke-free air in ... momentum behind smoke-free air laws will continue accelerating because ... to protect the public from secondhand smoke. ...
... announced today the presentation of new analysis of data ... on the clinical development of their investigational drug, Viprinex(TM) ... the 16th annual European Stroke Congress in Glasgow, Scotland ... derived from the venom of the Malayan pit viper. ...
... our nation, Americans are very optimistic about the war ... nationwide survey sponsored by Abbott, nearly two-thirds (64%) believe ... ,"As an organization researching new options to ... will live up to the optimism expressed by Americans ...
... global public health community observes World No Tobacco Day, the ... epidemic that tobacco causes for our nation. Two important new ... can address the deadly toll of tobacco -- especially secondhand ... Tobacco Day. ,The Institute of Medicine, the group ...
Cached Medicine News:Health News:Growth of Smoke-Free Air Laws Worldwide; More Than 200 Million Found "Fully Protected" 2Health News:Investigational Drug Being Pursued for the Treatment of Ischaemic Stroke 2Health News:Americans Optimistic About the War on Cancer 2Health News:World No Tobacco Day Focuses on Secondhand Smoke 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: